A Phase 1b/2 study to assess the safety, tolerability and efficacy of BGB-290 in combination with radiation therapy and/or temozolomide in subjects with first-line or recurrent/refractory glioblastoma
Study of Drug BGB-290 in Patients with Glioblastoma
Sponsor: BeiGene, Ltd.
Enrolling: Male and Female Patients
IRB Number: AAAR6842
U.S. Govt. ID: NCT03150862
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information: The purpose of this study is to look at the effects of an investigational anti-cancer drug (BGB-290) in combination with radiation therapy and/or temozolomide in patients with newly diagnosed or recurring glioblastoma. BGB-290 is expected to work by preventing cancer cells from repairing their damaged genes, causing the progression of cancer to slow down.
This study is closed
Andrew Lassman, MD
Do You Qualify?
Are you 18 years or older? Yes No
Do you have a diagnosis of glioblastoma? Yes No
If you were recently diagnosed with glioblastoma, have you received treatment for your glioblastoma other than surgery? Yes No
If your glioblastoma has recently recurred, have you only received chemotherapy treatment with temozolomide? Yes No
You may be eligible for this study

Place Holder

For more information, please contact:
Research Nurse Navigator